Longeveron Inc. - Class A Common stock (LGVN)

Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.

Longeveron Inc. (LGVN) reported Q2 2025 earnings with revenue missing estimates at $320K but a narrower EPS loss of $0.33. Stock fell 3.5% post-earnings amid clinical progress in HLHS and Alzheimer's trials.

Curious to know what's happening on the US markets one hour before the close of the markets on Friday? Join us as we explore the top gainers and losers in today's session.

After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

After the closing bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

The good news on Lomecel-B comes at an opportune time for Longeveron and LGVN stock -- it could attract a buyer.

LGVN stock results show that Longeveron missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

A look at the most-searched tickers on Benzinga Pro for the month of July shows some familiar names like Tesla, Nvidia and Apple. Here's a look at the others.

Small-cap stocks are on the rise once again as the Federal Reserve ponders cutting interest rates, which has held back the sector.

Cognition Therapeutics stock is down on Monday after CGTX investors read the latest data from a Phase 2 clinical trial report.

Longeveron presented promising Phase 2a clinical trial data for Lomecel-B at the AAIC 2024. The trial showed the drug's safety and efficacy in treating Alzheimer's, demonstrating slowed disease progression, improved daily living activities, and minimized brain volume loss.